Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The option agreement grants Soligenix the right to acquire a novel topical formulation of SRT001 (pentoxifylline), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).
Lead Product(s): Pentoxifylline
Therapeutic Area: Rare Diseases and Disorders Product Name: SRT001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Soligenix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 01, 2023